arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

enGene Therapeutics Inc.

ENGN Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$1.56
▼ -4.3% Today
as of Oct 23, 14:17 ET
Last 30 days -16.58% Sep 14 → Oct 23
$1.52 $1.66 $1.80 $1.95 $2.09 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$1.62
High
$1.65
Low
$1.57
Volume
$554,575
Avg Vol
$1M
Mkt Cap
$128M
P/E (TTM)
—
Beta
—
52w High
$12.25
52w Low
$1.40
Div Yield
—
Shares Out
$67M

Recent Press Releases & News last 60 days · 4 items

Oct 16 · 05:02 MarketBeat
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
Oct 13 · 12:00 PR Business Wire
enGene to Host KOL Webinar on October 15, 2026
Sep 8 · 11:30 PR Business Wire
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
▸ Show all 4 press releases & news Free account →

ENGN earnings at a glance

The options market is pricing a move of about ±22.3% after the report, a range of roughly $1.21 to $1.91 from today's $1.56. Over its last 1 reports the stock rose the next day 1 time and fell 0, moving ±0.9% on average; after the most recent report on Jun 12, 2025 it moved +0.9%. That means options currently expect more movement than ENGN has typically delivered. ENGN beat the consensus EPS estimate in 0 of its last 2 reported quarters. Implied volatility is currently 112%. The share price of $1.56 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.40
$12
1% of range
Avg surprise (last 2)
-9.2%
Avg reaction (last 1)
+0.9%
100% positive
Latest IV / EM
112%
EM ±22.3% · $2 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.57$1.90$4.37$6.83$9.30 Actual $9.30Actual $8.55Actual $0.46Actual $0.38Actual $0.32Actual $0.48Actual $-0.51Actual $-0.51Est $-0.50Actual $-0.57Est $-0.49Actual $0.44Actual $-0.43Actual $-0.47 AprJulJanAprJulJanAprApr/2025Jul/2025JanAprJul
Revenue vs Net Income Revenue Net income
$-33M$-31M$-29M$-28M$-26M Jan 25Apr 25Jul 25Jan 26Apr 26Jul 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Fri Jul 31, 2026Jul 2026 $-0.47 — — — — financials
Thu Apr 30, 2026Apr 2026 $-0.43 — — — — financials
Sat Jan 31, 2026Jan 2026 $0.44 — — — — financials
Thu Sep 11, 2025Jul/2025 $-0.57 $-0.49 -16.3% — — earnings
Thu Jun 12, 2025Apr/2025 $-0.51 $-0.50 -2.0% — +0.9% earnings
Wed Apr 30, 2025Apr 2025 $-0.51 — — — — financials
Fri Jan 31, 2025Jan 2025 $0.48 — — — — financials
Wed Jul 31, 2024Jul 2024 $0.32 — — — — financials
Tue Apr 30, 2024Apr 2024 $0.38 — — — — financials
Wed Jan 31, 2024Jan 2024 $0.46 — — — — financials
Mon Jul 31, 2023Jul 2023 $8.55 — — — — financials
Sun Apr 30, 2023Apr 2023 $9.30 — — — — financials
Tue Jan 31, 2023Jan 2023 $13.29 — — — — financials

Financials

Income statement (quarterly)

MetricJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-34M$-32M$-31M—$-30M$-27M$-27M—
Net income$-33M$-30M$-30M—$-29M$-26M$-25M—
EPS (diluted)$-0.47$-0.43$0.44—$-0.57$-0.51$0.48—

Balance sheet (quarterly)

MetricJul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Cash & equivalents$41M$30M$37M$50M$33M$58M$62M$173M
Inventory————————
Total current assets$278M$270M$289M$201M$211M$228M$222M$247M
Total assets$288M$308M$337M$221M$246M$267M$286M$311M
Long-term debt————————
Total liabilities$58M$52M$56M$54M$45M$39M$36M$39M
Total equity$230M$255M$282M$168M$201M$227M$250M$273M

Implied volatility — last 90 days

39%1016%1994%2971%3948% Jun 06 — IV 145% · EM ±25.7%Jun 07 — IV 330% · EM ±45.7%Jun 08 — IV 413% · EM ±54.5%Jun 09 — IV 358% · EM ±44.9%Jun 10 — IV 476% · EM ±56.2%Jun 11 — IV 441% · EM ±48.8%Jun 12 — IV 573% · EM ±58.6%Jun 15 — IV 469% · EM ±33.9%Jun 16 — IV 580% · EM ±34.3%Jun 17 — IV 1170% · EM ±48.9%Jun 19 — IV 39% · EM ±8.7%Jun 22 — IV 43% · EM ±8.9%Jun 23 — IV 43% · EM ±8.9%Jun 30 — IV 50% · EM ±8.7%Jul 06 — IV 94% · EM ±13.1%Jul 07 — IV 118% · EM ±15.6%Jul 08 — IV 86% · EM ±10.8%Jul 09 — IV 91% · EM ±10.8%Jul 14 — IV 333% · EM ±24.1%Jul 15 — IV 401% · EM ±23.7%Jul 20 — IV 45% · EM ±10.7%Jul 21 — IV 45% · EM ±10.4%Jul 22 — IV 47% · EM ±10.8%Jul 23 — IV 59% · EM ±13.2%Jul 24 — IV 50% · EM ±11.0%Jul 27 — IV 54% · EM ±11.2%Jul 28 — IV 56% · EM ±11.4%Jul 29 — IV 56% · EM ±11.2%Jul 30 — IV 57% · EM ±11.2%Aug 24 — IV 86% · EM ±18.0%Aug 25 — IV 88% · EM ±18.0%Aug 26 — IV 122% · EM ±24.4%Aug 27 — IV 86% · EM ±16.8%Aug 28 — IV 143% · EM ±27.4%Aug 31 — IV 184% · EM ±32.6%Sep 01 — IV 188% · EM ±32.3%Sep 02 — IV 174% · EM ±29.1%Sep 03 — IV 180% · EM ±29.1%Sep 09 — IV 194% · EM ±24.3%Sep 10 — IV 218% · EM ±25.7%Sep 11 — IV 277% · EM ±30.6%Sep 14 — IV 288% · EM ±24.1%Sep 15 — IV 366% · EM ±26.5%Sep 16 — IV 443% · EM ±26.2%Sep 17 — IV 3949% · EM ±164.9%Sep 22 — IV 108% · EM ±22.1%Sep 23 — IV 112% · EM ±22.3%

Sector peers

TNYA
Tenaya Therapeutics, Inc.
$127M $0.39+0.3%
CRBU
Caribou Biosciences, Inc.
$131M $0.540.0%
ARMP
Armata Pharmaceuticals, Inc.
$123M $3.71+21.2%
HUMA
Humacyte, Inc.
$140M $0.43+3.9%
LENZ
LENZ Therapeutics, Inc.
$114M $3.10-3.9%
MOLN
Molecular Partners AG
$143M $3.67-1.3%

ENGN earnings FAQ

What is ENGN's expected move for earnings?

Options currently price a move of about ±22.3%, or $0.35 per share either way from $1.56.

How does ENGN stock usually react to earnings?

Across the last 1 reports the average next-day move was ±0.9%, up 1 times and down 0 times.

What is ENGN's implied volatility?

ENGN's at-the-money implied volatility is about 112% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in